Skip to search.
 FTSE 100 Up0.08%

More On SHP.L



  • Warrants
  • Investment Products


News & Info


Analyst Coverage



Shire PLC (SHP.L)

4,289.00 Down 60.00(1.38%) 27 May 16:35
ProfileGet Profile for:
Shire PLC
5 Riverwalk
Citywest Business Campus
Dublin, 24
Ireland - Map
Phone: 353 1 429 7700

Index Membership:N/A
Full Time Employees:5,548

Business Summary 

Shire plc, a biotech company, together with its subsidiaries, engages in the research, development, licensing, manufacture, marketing, distribution, and sale of medicines for patients with rare diseases and other select conditions. Its principal products for the treatment of attention deficit hyperactivity disorder (ADHD) and binge eating disorder include VYVANSE/VENVANSE/ELVANSE/TYVENSE/ELVANSE VUXEN/ADUVANZ, as well as ADDERALL XR and INTUNIV for the treatment of ADHD; and LIALDA/MEZAVANT for the treatment of ulcerative colitis. The company also offers REPLAGAL for the treatment of Fabry disease; ELAPRASE for the treatment of hunter syndrome; VPRIV for the treatment of type 1 Gaucher disease; FIRAZYR and CINRYZE C1 esterase inhibitor for the treatment of hereditary angioedema; GATTEX/REVESTIVE for the treatment of short bowel syndrome; and NATPARA/NATPAR used to control hypocalcemia in patients with hypoparathyroidism. In addition, it provides Fosrenol for the treatment of hyperphosphatemia in end stage renal disease. Further, the company licenses its patented antiviral products for human immunodeficiency virus and hepatitis B virus. Additionally, it focuses on its development resources on projects in various therapeutic areas, including rare diseases, neuroscience, ophthalmics, hematology, and gastrointestinal disorders; and early development projects, primarily on rare diseases. Shire plc markets its products through wholesalers and pharmacies. The company has collaboration and licensing activities with ArmaGen Inc.; Sangamo BioSciences, Inc.; and Shionogi Pharma, Inc. Shire plc was founded in 1986 and is based in Dublin, Ireland.

Key Statistics

Company Websites 
Home Page
Search Yahoo! UK & Ireland for:
More on Shire PLC

Key Executives 
Dr. Flemming Ornskov M.D., MBA, MPH, 58
Chief Exec. Officer, Managing Director and Director
Mr. Jeffrey Poulton , 48
Chief Financial Officer and Director
Ms. Marianne Jackson ,
Head of Global Commercial Operations
Mr. William Ciambrone ,
Head of Technical Operations
Mr. William R. Mordan , 46
Gen. Counsel and Corp. Sec.
Amounts are as of 31 Dec 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year.
Currency in GBp.
View Insiders